For research use only
| Cat No. | ABC-SC0087 |
| Product Type | Human Cancer Stem Cells |
| Cell Type | Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Liver |
| Disease | Liver Cancer |
| Storage | Liquid Nitrogen |
Human Liver Cancer Stem Cell; Frozen Vial and Plated cells are available.
HighQC™ Human Liver Cancer Stem Cells are derived from hepatocellular carcinoma (HCC) specimens and cultured under defined, serum-free, stem cell-selective conditions to enrich tumor-initiating subpopulations. HighQC™ Human Liver Cancer Stem Cells exhibit both epithelial-like and mesenchymal-like morphologies, reflecting the plasticity and heterogeneity typical of LCSCs. They express liver CSC-associated markers including CD 44, CD133, SSEA3/4, Oct4. They demonstrate hallmark properties of cancer stem cells, including enhanced self-renewal, tumorigenicity, and resistance to chemotherapeutic agents. Functionally, they contribute to tumor heterogeneity and recurrence, playing a pivotal role in HCC progression and treatment failure. These liver CSCs provide a robust platform for modeling hepatocarcinogenesis, drug screening, and evaluating immunotherapeutic responses. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | HighQC™ Human Liver Cancer Stem Cell, Human HCC CSC, hHCC-CSC, Human Hepatocellular CSC |
| Species | Human |
| Cat.No | ABC-SC0087 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Liver |
| Disease | Liver Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Cancer Stem Cells |
HighQC™ Human Liver Cancer Stem Cells serve as a valuable tool for studying hepatocellular carcinoma pathogenesis, chemoresistance, and metastasis. Researchers use these cells to develop CSC-targeted therapies, investigate signaling pathways such as Wnt/β-catenin and TGF-β, and create patient-representative xenograft models. These CSCs also support exploration of liver tumor heterogeneity, relapse mechanisms, and immunotherapeutic responses in HCC.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).